LB-101 is under clinical development by Centessa Pharmaceuticals and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LB-101 overview

LB-101 is under development for the treatment of solid tumors, non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, cutaneous squamous cell carcinoma, metastatic colorectal cancer and metastatic ovarian cancer.  It is a bi-specific monoclonal antibody acts by targeting PDL1 and CD47. It is developed based on LockBody technology. It is administered through intravenous route.

Centessa Pharmaceuticals overview

Centessa Pharmaceuticals is a next-generation biopharmaceutical firm aiming to reinvent the medication development process. The company is headquartered in Cambridge, England, the UK.

For a complete picture of LB-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.